CD8A and non-small cell lung carcinoma: In NSCLC, together with other malignancies, many studies have evaluated the clinical value of CD8+ cells alone or combined with other biomarkers, demonstrating a strong independent positive prognostic effect regardless of tissue compartments evaluated [10-16].